KORU Medical Seeks FDA Clearance for FreedomEDGE Infusion System in Q4 2025/Q1 2026

martes, 18 de noviembre de 2025, 6:42 am ET1 min de lectura
KRMD--

KORU Medical Systems plans to submit a 510(k) application to the FDA for its FreedomEDGE Syringe Infusion System in Q4 2025/Q1 2026, seeking clearance for use with a commercialized oncology drug. The system enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs, supporting volumes from 5 mL to 50 mL+. The company will present data from a multicenter study at the ESID/EHA/SIOPE Focused Symposium in Vienna, Austria.

KORU Medical Seeks FDA Clearance for FreedomEDGE Infusion System in Q4 2025/Q1 2026

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios